GlassScriptPhysician profile
Kamalesh Bala
NPI 1093017253
$6,887.54
in general payments reported to CMS, 2019-2025
13 companies · $1,936 in 2025
The $1,936 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.48 · 2020: $1,200 · 2021: $1,862 · 2022: $1,144 · 2023: $35.08 · 2024: $643 · 2025: $1,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,035 · Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,035.00 |
| Food and Beverage | $579.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,294.61 | 2022-2025 | Vanflyta, Enhertu, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,370.58 | 2021-2025 | |
| Celgene Corporation | $1,200.00 | 2020 | |
| Incyte Corporation | $860.00 | 2025 | |
| Astellas Pharma US INC | $500.00 | 2021 | |
| Merck Sharp & Dohme LLC | $269.78 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $142.47 | 2024-2025 | Tagrisso, Imfinzi |
| Lilly USA, LLC | $84.99 | 2025 | |
| Exelixis INC. | $55.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.95 | 2022 | |
| Seagen INC. | $27.76 | 2019-2023 | Adcetris |
| Janssen Biotech, INC. | $26.29 | 2025 | Talvey, Tecvayli |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamalesh Bala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.